Measuring nucleosomes using nu.q® nets is a promising biomarker for septic shock

Henderson, nev. , oct. 19, 2023 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, announces the publication of a clinical paper1 which shows that volition's nu.q® nets test is a promising biomarker for the evaluation of disease severity in septic shock patients and could play an important role in sepsis prognosis.
VNRX Ratings Summary
VNRX Quant Ranking